All In Biotech

Investigational drug · Phase 2

HLX01

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Membranous Nephropathy, Lupus Nephritis (LN).

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

11

Any phase or sponsor naming "HLX01"

First trial start

2025

Aug 5, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HLX01", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Membranous Nephropathy
  • Lupus Nephritis (LN)

Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "HLX01" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 8 on PubMed

Also in development for Membranous Nephropathy

  • PovetaciceptALPN-303Phase 37 trials

    Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy

  • HLX79Phase 21 trial

    Shanghai Henlius Biotech · Membranous Nephropathy, Lupus Nephritis (LN)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.